TABLE 1.
Demographic, clinical, and imaging data of patients with progressive supranuclear palsy‐parkinsonism, patients with Parkinson's disease, and control subjects in the training and testing cohorts
| Training Cohort | Testing Cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| Data | PSP‐P (n = 43) | PD (n = 177) | Control Subjects (n = 92) | P Value | PSP‐P (n = 56) | PD (n = 166) | Control Subjects (n = 91) | P Value |
| Sex (M/F) | 29/14 | 104/73 | 45/47 | 0.113 a | 37/19 | 100/66 | 47/44 | 0.200 a |
| Age at examination, y (mean ± SD) | 71.7 ± 5.5 b , c | 65.8 ± 8.4 d | 63.2 ± 8.5 | <0.001 e | 70.6 ± 6.1 b , c | 64.7 ± 9.5 | 63.7 ± 8.9 | <0.001 e |
| Age at disease onset, y (mean ± SD) | 65.7 ± 6.2 b | 59.7 ± 8.6 | / | <0.001 f | 66.8 ± 6.5 b | 59.4 ± 9.6 | / | <0.001 f |
| Disease duration, y (mean ± SD) | 5.9 ± 3.5 | 6.1 ± 3.8 | / | 0.570 f | 4.1 ± 2.2 | 5.3 ± 4.1 | / | 0.240 f |
| MDS‐UPDRS‐III score, median (range) | 37 (16–55) b | 27 (6–66) | / | <0.001 g | 40 (15–64) b | 24 (4–68) | / | <0.001 g |
| H‐Y score, median (range) | 3 (2–5) b | 2 (1–4) | / | <0.001 g | 3 (2–5) b | 2 (1–4) | / | <0.001 g |
| Brain MRI automated measurements | ||||||||
| MRPI (mean ± SD) | 14.28 ± 3.98 b , c | 9.90 ± 3.35 | 9.48 ± 1.81 | <0.001 g | 16.53 ± 5.98 b , c | 10.25 ± 2.26 | 9.80 ± 2.19 | <0.001 g |
| 3 V width, mm (mean ± SD) | 8.61 ± 2.44 b , c | 5.17 ± 2.10 | 4.29 ± 1.70 | <0.001 g | 9.79 ± 2.62 b , c | 5.99 ± 2.23 | 5.32 ± 2.16 | <0.001 g |
| 3 V/FHs ratio (mean ± SD) | 0.22 ± 0.05 b , c | 0.15 ± 0.05 d | 0.12 ± 0.04 | <0.001 g | 0.25 ± 0.05 b , c | 0.16 ± 0.05 | 0.14 ± 0.05 | <0.001 g |
| MRPI 2.0 (mean ± SD) | 3.25 ± 1.32 b , c | 1.48 ± 0.83 | 1.20 ± 0.53 | <0.001 g | 4.26 ± 2.16 b , c | 1.65 ± 0.76 | 1.47 ± 0.72 | <0.001 g |
The disease onset was defined as the onset of the first PSP‐related symptom (motor or nonmotor), according to the Movement Disorder Society criteria for PSP clinical diagnosis.
PSP‐P, progressive supranuclear palsy‐parkinsonism; PD, Parkinson's disease; M, male; F, female; MDS‐UPDRS‐III, Movement Disorder Society–Unified Parkinson's Disease Rating Scale Part III (motor examination); H‐Y, Hoehn and Yahr rating scale; MRI, magnetic resonance imaging; MRPI, Magnetic Resonance Parkinsonism Index; 3 V, third ventricle; FH, frontal horn.
Fisher's exact test.
P < 0.001 (PSP‐P versus PD).
P < 0.001 (patients versus control subjects).
P < 0.05 (patients versus control subjects).
Kruskal–Wallis test followed by pairwise Wilcoxon rank sum test.
Wilcoxon rank sum test.
Analysis of covariance with age and sex as covariates, followed by Tukey test. The scanner field strength (1.5 and 3.0 T) was also included as covariate in the testing cohort; the MDS‐UPDRS‐III score was also included as covariate in the PSP‐P versus PD comparison in both cohorts. All P values were corrected according to Bonferroni.